比热戈斯群岛疟疾控制的辅助伊维菌素群体给药(MATAMAL):四盲、整群随机、安慰剂对照试验
MATAMAL试验在几内亚比绍比热戈斯群岛将24个整群按1:1随机,比较双氢青蒿素-哌喹联合伊维菌素或安慰剂的群体给药;干预后恶性疟原虫感染率对照组为5.05%(118/2300)、干预组为6.64%(141/2083),调整风险差1.67%(95%CI -1.44至4.78;p=0.28),按蚊经产率调整风险差-1.32(95%CI -14.77至12.12;p=0.84),加用伊维菌素未额外降低疟疾患病率或媒介经产率,耐受性良好。
要点
- 干预后恶性疟原虫感染率对照组5.05%(118/2300)vs干预组6.64%(141/2083),调整风险差1.67%(95%CI -1.44至4.78;p=0.28)。
- 按蚊经产率对照群67.8%(1679/2475)vs干预群72.3%(1740/2414),调整风险差-1.32(95%CI -14.77至12.12;p=0.84)。
- 不良事件对照组124例(占参与者1.0%)vs干预组267例(占参与者1.9%),2例严重不良事件均与干预无关,无治疗相关死亡。
核心结论
- 在该研究环境中,将伊维菌素加入双氢青蒿素-哌喹群体给药对降低疟疾患病率或媒介经产率无额外效果。
- 该干预耐受性良好。
- 据作者所知,该试验是首个设计用于评估伊维菌素与双氢青蒿素-哌喹群体给药联合应用时对疟疾是否具有附加效果的试验。
研究设计与样本
- MATAMAL为四盲、整群随机、安慰剂对照试验,在几内亚比绍比热戈斯群岛季节性疟疾传播地区开展。
- 所有居民被邀请参与,排除标准为药物安全性。
- 24个整群按1:1比例采用限制性随机化分组,分别接受三个连续月份每月连续三日口服双氢青蒿素-哌喹加伊维菌素(300 μg/kg每日)或双氢青蒿素-哌喹加安慰剂,于2021年和2022年传播季节实施。
- 主要结局为干预第二年传播高峰时所有年龄组恶性疟原虫血症的定量PCR患病率;主要昆虫学结局为按蚊经产率。
- 试验注册于ClinicalTrials.gov(NCT04844905)。
主要发现
- 参与者于2021年6月7日至2022年9月21日招募;基线人口25882人(女性12634人[50.6%],男性12317人[49.4%]),干预组13832人,对照组12050人。
- 双氢青蒿素-哌喹的整群覆盖率范围为60.4%至78.7%,伊维菌素或伊维菌素-安慰剂为58.1%至77.1%。
- 干预后恶性疟原虫感染率对照组为5.05%(118/2300),干预组为6.64%(141/2083);调整风险差1.67%(95%CI -1.44至4.78;p=0.28)。
- 不良事件对照组124例(占参与者1.0%),干预组267例(占参与者1.9%);报告2例严重不良事件,均与干预无关,无治疗相关死亡。
- 按蚊经产率对照群为67.8%(1679/2475),干预群为72.3%(1740/2414);调整风险差-1.32(95%CI -14.77至12.12;p=0.84)。
临床怎么用
- 原文结论为在该研究环境中将伊维菌素加入双氢青蒿素-哌喹群体给药对降低疟疾患病率或媒介经产率无额外效果,未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Arthropod vectors feeding on the blood of individuals treated with ivermectin have substantially increased mortality. Whether this effect will translate into a useful tool for reducing malaria burden at scale is not clear. Our trial aimed to assess whether using ivermectin as an adjunct to mass drug administration (MDA) with dihydroartemisinin-piperaquine would further reduce malaria prevalence. METHODS: MATAMAL was a quadruple-blinded, cluster-randomised, placebo-controlled trial, conducted on the Bijagos Archipelago, Guinea-Bissau, an area of seasonal malaria transmission. All residents were invited to participate, with exclusions for drug safety. 24 clusters were randomised in a 1:1 ratio, using restriction randomisation, to either MDA with three daily oral doses of dihydroartemisinin-piperaquine and ivermectin (300 μg/kg per day) in three sequential months during the transmission season in 2021 and 2022, or MDA with dihydroartemisinin-piperaquine and placebo in the same schedule. The primary outcome was quantitative PCR prevalence of Plasmodium falciparum parasitaemia in all age groups, during peak transmission, after the second year of intervention. The primary entomological outcome was anopheline parity rate. The trial is registered with ClinicalTrials.gov (NCT04844905). FINDINGS: Participants were recruited between June 7, 2021 and Sept 21, 2022. The baseline population was 25 882 (12 634 [50·6%] were female individuals and 12 317 [49·4%] were male individuals): 13 832 were in the intervention group and 12 050 in the control group. Cluster-level coverage for dihydroartemisinin-piperaquine ranged from 60·4% to 78·7%, and for ivermectin or ivermectin-placebo from 58·1 to 77·1%. Following the intervention, the prevalence of P falciparum infection was 118 (5·05%) of 2300 in the control group and 141 (6·64%) of 2083 in the intervention group. The adjusted risk difference was 1·67% (95% CI -1·44 to 4·78; p=0·28). There were 124 adverse events in the control group (1·0% of participants) and 267 in the intervention group (1·9% of participants). Two serious adverse events were reported, neither related to the intervention, and no treatment-related deaths. The anopheline parity rate was 1679 (67·8%) of 2475 in control clusters and 1740 (72·3%) of 2414 in intervention clusters. The adjusted risk difference was -1·32 (95% CI -14·77 to 12·12; p=0·84). INTERPRETATION: Adding ivermectin to dihydroartemisinin-piperaquine MDA had no additional effect on reducing malaria prevalence or vector parity in this setting. The intervention was well tolerated. To our knowledge, this trial is the first to be designed to assess whether ivermectin has an additive effect on malaria when coadministered with dihydroartemisinin-piperaquine MDA. FUNDING: The National Institute for Health and Care Research, Medical Research Council, Wellcome, and Foreign, Commonwealth & Development Office.
引用
- Hutchins H, Pretorius E, Bradley J, et al. Adjunctive ivermectin mass drug administration for malaria control on the Bijagos Archipelago of Guinea-Bissau (MATAMAL): a quadruple-blinded, cluster-randomised, placebo-controlled trial. Lancet Infect Dis. 2024. PMID: 39551062. doi:10.1016/S1473-3099(24)00580-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。